Market Crash: 2 Healthcare Stocks Worth Loading Up on at a Discount

The article highlights two healthcare names, Intuitive Surgical and Abbott Laboratories, as buying opportunities after recent market weakness. Intuitive’s revenue rose 19% and Da Vinci procedures increased 17%, while its valuation eased to 45x forward earnings from 60x earlier this year. Abbott was cited for diversification, Dividend King status, and a lower valuation at 17x forward earnings, down from more than 22x earlier in 2026.

Analysis

The move lower in both names looks more like multiple compression than a deterioration in the operating setup. In a choppy tape, investors have been paying up for duration and then rapidly de-risking on anything with a premium valuation, which creates a window where quality healthcare franchises can re-rate simply because their cash flows are less cyclical than the market is pricing. The bigger second-order effect is that capital is rotating toward predictable repeat-revenue models, and that tends to reward companies with installed-base economics and recurring consumables more than headline growth alone.

ISRG’s setup is still dominated by the adoption curve, not the quarter-to-quarter earnings print. The key near-term catalyst is utilization: once procedure growth stays ahead of system placements for several quarters, the market starts treating the platform as an annuity rather than a capital equipment story. That matters because it supports margin durability and makes the valuation gap to the rest of high-quality medtech look less extreme than it appears on a trailing basis; the risk is not competition today, but any slowdown in hospital purchasing budgets that could temporarily soften system sales without meaningfully harming long-term instrument pull-through.

ABT is the cleaner defensive compounder because it has more internal offsets if one end market stalls. The contrarian point is that the market may be underestimating how valuable that diversification becomes if rates stay elevated and reimbursement remains pressured: slower procedure volumes can hurt pure-play device peers more than a multi-franchise operator with pricing power and dividend support. The dividend story is not just income appeal; it acts as a valuation floor in risk-off periods, which can attract incremental ownership from lower-volatility mandates over the next 3-6 months.

Net: this is a buy-the-dip setup only if you are willing to own duration. The risk is that the broader market de-risks again and compresses premium multiples another 10-15%, in which case these names can stay cheap longer than expected; the catalyst to watch is whether medical procedure volumes and hospital capex hold up through the next earnings season, because that will determine whether the pullback was an entry point or the start of a longer de-rating.

Key Decisions for Investors

• Go long ISRG on weakness over the next 1-3 weeks; target a 6-12 month hold. Risk/reward favors patient buying because the downside is mostly multiple compression, while upside comes from a re-acceleration in procedure growth and renewed premium support.
• Initiate a long ABT position as a defensive quality compounder for the next 3-6 months. Use it as a lower-volatility healthcare core holding with dividend support and better downside capture than pure-play medtech.
• Pair trade: long ABT / short a more economically sensitive healthcare device basket for 1-2 quarters. The thesis is that diversification and dividend support should outperform names whose earnings are more exposed to delayed hospital capex decisions.
• For tactical traders, use ISRG call spreads rather than outright stock for the next earnings cycle. The better entry is after any post-print volatility, since the stock can gap on sentiment even when fundamentals remain intact.
• Set a stop on ISRG if procedure growth clearly decelerates for two consecutive quarters; that would weaken the annuity narrative and likely extend the de-rating.